2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P4843
    Gastric Inhibitory Polypeptide (6-30) amide (human) 1139691-72-7 98%
    Gastric Inhibitory Polypeptide (6-30) amide (human) is an incretin hormone. Gastric Inhibitory Polypeptide (6-30) amide (human) can be used for the research of diabete.
    Gastric Inhibitory Polypeptide (6-30) amide (human)
  • HY-P4890
    Relaxin H3 (human) 1158181-62-4 98%
    Relaxin H3 (human) is a relaxin peptide with anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective and anti-fibrotic activities. Relaxin H3 (human) acts on RXFP1 to generate cAMP and reduce the levels of ATP and ROS. Relaxin H3 (human) inhibits renal inflammatory pyroptosis (pyroptosis), NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling pathway, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration. Relaxin H3 (human) activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, inhibits apoptosis (apoptosis) and pyroptosis, restores retinal ultrastructure, and reverses excessive left ventricular collagen expression. Relaxin H3 (human) can be used in studies related to kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
    Relaxin H3 (human)
  • HY-P5063
    Galanin-Like Peptide (human) 245114-99-2 98%
    Galanin-Like Peptide (human) is a 60 amino acid neuropeptide. Galanin-Like Peptide (human) plays an important role in the regulation of feeding, body weight and energy metabolism.
    Galanin-Like Peptide (human)
  • HY-P5065
    Galanin-Like Peptide (rat) 245114-97-0 98%
    Galanin-Like Peptide (rat) is a 60 amino acid neuropeptide. Galanin-Like Peptide (rat) plays an important role in the regulation of feeding, body weight and energy metabolism.
    Galanin-Like Peptide (rat)
  • HY-P5069
    Glutathione diethyl ester 97451-40-6 98%
    Glutathione diethyl ester is a delivery agent for glutathione monoester, and thus for glutathione, in human cells and therefore could serve to decrease oxidative stress and toxicity.
    Glutathione diethyl ester
  • HY-P5072
    GRP (14-27) (human, porcine, canine) 81608-29-9 98%
    GRP (14-27) (human, porcine, canine) is a bombesin receptor ligand. The specific binding of GRP (14-27) is inhibited by GTP and GDP, whereas GMP was without effect.
    GRP (14-27) (human, porcine, canine)
  • HY-P5077
    Guanylin (mouse, rat) 145257-03-0 98%
    Guanylin (mouse, rat), a petide, is composed of 15 amino acids. Guanylin (mouse, rat) is an activator of intestinal guanylate cyclase. Guanylin (mouse, rat) can be used for the research of diarrhea.
    Guanylin (mouse, rat)
  • HY-P5140
    ω-Tbo-IT1 98%
    ω-Tbo-IT1 is a peptide toxin that can be isolated from the venom of Tibellus oblongus.ω-Tbo-IT1 is an inhibitor of insect calcium channel.
    ω-Tbo-IT1
  • HY-P5161
    FC382K10W15 98%
    FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research.
    FC382K10W15
  • HY-P5249
    KLKKTETQ 1054611-00-5 98%
    KLKKTETQ is a bioactive peptide with anti-aging effect and has been reported used as a cosmetic ingredient.
    KLKKTETQ
  • HY-P5252
    Diaminopropionoyl tripeptide-33 1199495-15-2 98%
    Diaminopropionoyl tripeptide-33isa bioactive peptide with protects skin cells from UVA-induced DNA damages and has been reported used as a cosmetic ingredient.
    Diaminopropionoyl tripeptide-33
  • HY-P5254
    Hexapeptide-3 1205679-02-2 98%
    Hexapeptide-3isa bioactive peptide with repair skin effect and has been reported used as a cosmetic ingredient.
    Hexapeptide-3
  • HY-P5258
    Oligopeptide-41 98.05%
    Oligopeptide-41 is a bioactive peptide with promotion of hair growth effect and has been reported used as a cosmetic ingredient.
    Oligopeptide-41
  • HY-P5259
    Oligopeptide-6 98%
    Oligopeptide-6 is a bioactive peptide with moisturizing effect and has been reported used as a cosmetic ingredient.
    Oligopeptide-6
  • HY-P5260
    Oligopeptide-74 98%
    Oligopeptide-74 is a bioactive peptide with promotion of hair growth effect and has been reported used as a cosmetic ingredient.
    Oligopeptide-74
  • HY-P5262
    Tripeptide-10 515835-71-9 98%
    Tripeptide-10 is a bioactive peptide withanti-wrinkleeffect and has been reported used as a cosmetic ingredient.
    Tripeptide-10
  • HY-P5267
    Palmitoyl dipeptide-7 911813-90-6 98%
    Palmitoyl dipeptide-7 is a bioactive peptide with anti-aging effect and has been reported used as a cosmetic ingredient.
    Palmitoyl dipeptide-7
  • HY-P5268
    Palmitoyl hexapeptide-14 891498-01-4 98%
    Palmitoyl hexapeptide-14(Palmitoyl hexapeptide-6)isa bioactive peptide withanti-inflammatoryeffect and has been reported used as a cosmetic ingredient.
    Palmitoyl hexapeptide-14
  • HY-P5279
    Palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine 2228114-98-3 98%
    Palmitoyl dipeptide-7 is a bioactive peptide with anti-aging effects that has been reported for use as a cosmetic ingredient.
    Palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine
  • HY-P5291
    CPF-7 103238-06-8 98%
    CPF-7 (Caerulein precursor fragment) is an insulin-releasing peptide that stimulates the release of insulin. CPF-7 can induce epithelial-mesenchymal transition by upregulating Snai1 expression in PANC-1 ductal cells. CPF-7 also induces exocrine plasticity by upregulating Ngn3 expression. CPF-7 can be used in the research of type 2 diabetes.
    CPF-7
Cat. No. Product Name / Synonyms Application Reactivity